CR9993A - Formulación de suspensión de fexofenadina - Google Patents

Formulación de suspensión de fexofenadina

Info

Publication number
CR9993A
CR9993A CR9993A CR9993A CR9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A CR 9993 A CR9993 A CR 9993A
Authority
CR
Costa Rica
Prior art keywords
suspension formulation
fexofenadine
fexofenadine suspension
dihydrate
directed
Prior art date
Application number
CR9993A
Other languages
English (en)
Inventor
Agrawala Prafulla
Chrzan Kazimierz
Haribhkti Rajiv
Mermey Matthew
J Porcello Curtis
Lee Silvey Gary
Tran Vinh
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of CR9993A publication Critical patent/CR9993A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención está dirigida a una suspensión acuosa farmacéutica de Forma 1 dihidrato de fexofenadina de ion híbrido.
CR9993A 2005-12-14 2008-05-20 Formulación de suspensión de fexofenadina CR9993A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
CR9993A true CR9993A (es) 2008-09-23

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9993A CR9993A (es) 2005-12-14 2008-05-20 Formulación de suspensión de fexofenadina

Country Status (39)

Country Link
US (1) US8933097B2 (es)
EP (1) EP1965768B1 (es)
JP (1) JP5308824B2 (es)
KR (1) KR101452792B1 (es)
CN (1) CN101316580B (es)
AR (1) AR058323A1 (es)
AT (1) ATE431137T1 (es)
AU (1) AU2006326551B2 (es)
BR (1) BRPI0619895B1 (es)
CA (1) CA2633086C (es)
CR (1) CR9993A (es)
CY (1) CY1109320T1 (es)
DE (1) DE602006006870D1 (es)
DK (1) DK1965768T3 (es)
DO (1) DOP2006000274A (es)
EC (1) ECSP088532A (es)
EG (1) EG25866A (es)
ES (1) ES2327168T3 (es)
HK (1) HK1123197A1 (es)
HN (1) HN2008000875A (es)
HR (1) HRP20090411T1 (es)
IL (1) IL192067A (es)
JO (1) JO2549B1 (es)
MA (1) MA30152B1 (es)
MY (1) MY146988A (es)
NO (1) NO339877B1 (es)
NZ (1) NZ568943A (es)
PE (1) PE20071003A1 (es)
PL (1) PL1965768T3 (es)
PT (1) PT1965768E (es)
RS (1) RS51135B (es)
RU (1) RU2405538C2 (es)
SI (1) SI1965768T1 (es)
TN (1) TNSN08186A1 (es)
TW (1) TWI377061B (es)
UA (1) UA89584C2 (es)
UY (1) UY30021A1 (es)
WO (1) WO2007070517A2 (es)
ZA (1) ZA200803985B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
WO2013058996A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
TW201542240A (zh) * 2013-07-01 2015-11-16 Aventis Pharma Inc 包含菲索芬那定(fexofenadine)之口服液態醫藥組合物
JP2016523928A (ja) * 2013-07-03 2016-08-12 アール.ピー.シェーラー テクノロジーズ、エルエルシー フェキソフェナジンを有するカプセル製剤
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
EP3471725A4 (en) 2016-06-16 2020-01-22 Cutispharma, Inc. COMPOSITION AND METHOD FOR SUSPENDING A PROTON PUMP INHIBITOR
CN115569114A (zh) 2017-06-02 2023-01-06 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
AU693892B2 (en) 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
ATE444731T1 (de) 2003-01-30 2009-10-15 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
ES2704482T3 (es) * 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
WO2007017095A1 (en) 2005-07-27 2007-02-15 Sandoz Ag A process for the preparation of substituted phenyl ether compounds and rosiglitazone
WO2007017905A1 (en) * 2005-08-05 2007-02-15 Lupin Limited Oral pharmaceutical suspension compositions of fexofenadine

Also Published As

Publication number Publication date
DE602006006870D1 (de) 2009-06-25
IL192067A0 (en) 2009-02-11
BRPI0619895A2 (pt) 2011-10-25
PE20071003A1 (es) 2007-10-03
NZ568943A (en) 2010-04-30
BRPI0619895B1 (pt) 2022-04-12
TNSN08186A1 (en) 2009-10-30
HN2008000875A (es) 2012-01-30
CN101316580A (zh) 2008-12-03
ES2327168T3 (es) 2009-10-26
RS51135B (sr) 2010-10-31
AU2006326551A1 (en) 2007-06-21
ATE431137T1 (de) 2009-05-15
DK1965768T3 (da) 2009-09-07
PT1965768E (pt) 2009-08-07
NO339877B1 (no) 2017-02-13
KR20080074180A (ko) 2008-08-12
CA2633086C (en) 2011-10-18
SI1965768T1 (sl) 2009-10-31
PL1965768T3 (pl) 2009-11-30
US20080299211A1 (en) 2008-12-04
EP1965768A2 (en) 2008-09-10
EP1965768B1 (en) 2009-05-13
IL192067A (en) 2010-12-30
TW200812581A (en) 2008-03-16
JP2009519935A (ja) 2009-05-21
RU2405538C2 (ru) 2010-12-10
AR058323A1 (es) 2008-01-30
UY30021A1 (es) 2007-07-31
US8933097B2 (en) 2015-01-13
KR101452792B1 (ko) 2014-10-22
CA2633086A1 (en) 2007-06-21
NO20082904L (no) 2008-09-10
TWI377061B (en) 2012-11-21
UA89584C2 (en) 2010-02-10
CY1109320T1 (el) 2014-07-02
HK1123197A1 (en) 2009-06-12
MY146988A (en) 2012-10-15
MA30152B1 (fr) 2009-01-02
WO2007070517A2 (en) 2007-06-21
WO2007070517A3 (en) 2007-08-23
ZA200803985B (en) 2009-03-25
AU2006326551B2 (en) 2012-06-07
CN101316580B (zh) 2011-11-16
HRP20090411T1 (hr) 2010-01-31
DOP2006000274A (es) 2007-10-15
ECSP088532A (es) 2008-08-29
JP5308824B2 (ja) 2013-10-09
EG25866A (en) 2012-09-12
RU2008128418A (ru) 2010-01-20
JO2549B1 (en) 2010-09-05

Similar Documents

Publication Publication Date Title
CR9993A (es) Formulación de suspensión de fexofenadina
SG161311A1 (en) Novel use of spiegelmers
HRP20120323T1 (en) Diarylhydantoin compounds
RS54386B1 (en) ANTIVIRAL UNITS
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
RS53574B1 (en) PYROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS
UA105229C2 (uk) Фармацевтичний склад
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
GT200500360A (es) Compuestos organicos
ITMI20040076A1 (it) Procedimento per la preparazione di polibutadiene a basso grado di ranificazione
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
GT200500031A (es) Procesos para la preparacion de haluros de arilalquilsulfonilo y haluros de heteroarilalquilsulfonilo
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
ECSP088374A (es) Formulacion de aerosol para inhalacion
DOP2006000130A (es) Inhibidores de la adenilato ciclasa soluble

Legal Events

Date Code Title Description
FC Refusal